Four different questions
A zonulin claim may concern mechanism, measurement, association or clinical use. Mechanistic research asks how a biological pathway modulates junctional regulation. Biomarker research asks whether a measured characteristic tracks a defined process. Analytical research asks what an assay detects and how reliably. Clinical research asks whether the result supports a decision in a specified population.
These questions require different evidence. A plausible mechanism does not validate an assay. An analytically reproducible signal does not establish that the signal represents whole-barrier function. An association does not establish diagnosis, causation or clinical utility.
Biological pathway
The cited mechanistic literature describes zonulin/pre-haptoglobin-2 in relation to reversible modulation of tight junctions and paracellular permeability. This supports a pathway-level hypothesis and provides a framework for experiments.
The pathway is narrower than the barrier. It does not directly measure mucus, epithelial transport through cells, immune handling, microbial ecology or every junctional process. A pathway-specific result must remain specific unless additional measures support broader interpretation.
Analytical and biological validity
Analytical validity concerns identity, specificity, precision and reproducibility of the measurement process. Biological validity concerns whether the measured analyte reflects the intended biological process under the conditions studied. Population, specimen and timing influence that interpretation.
The current canonical library flags a source gap for assay-specific validity claims. Accordingly, this synthesis does not claim that commercial assays are analytically equivalent or that all reported zonulin values quantify the same molecular target. Heterogeneous measurements must be interpreted as heterogeneous unless direct validation demonstrates otherwise.
Intended use and clinical utility
A biomarker can have research value without being a diagnostic test. Intended use defines the decision a test is supposed to inform. Clinical utility requires evidence that use of the result benefits that decision or outcome in the relevant population.
The systematic-review evidence evaluates associations in defined paediatric mental-disorder research. It does not establish a universal diagnostic threshold, determine temporal direction, or demonstrate that modifying a measured marker changes clinical outcomes.
What the evidence supports
Mechanistic sources support a zonulin-related pathway of reversible paracellular regulation, while the verified review supports cautious synthesis of heterogeneous human marker studies.
The evidence supports keeping pathway, biomarker, assay and intended clinical use analytically separate.
What remains uncertain
Assay identity, cross-platform comparability and population-specific interpretation require direct validation sources beyond the current canonical library.
The reviewed evidence does not establish universal diagnostic validity, causal direction or clinical utility.
References
- Sturgeon C, Fasano A. Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases. Tissue Barriers 2016;4(4):e1251384. doi:10.1080/21688370.2016.1251384. DOI
- Tripathi A, Lammers KM, Goldblum S, et al. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proc Natl Acad Sci U S A 2009;106(39):16799–16804. doi:10.1073/pnas.0906773106. DOI
- Asbjornsdottir B, Snorradottir H, Andresdottir E, et al. Zonulin-Dependent Intestinal Permeability in Children Diagnosed with Mental Disorders: A Systematic Review and Meta-Analysis. Nutrients 2020;12(7):1982. doi:10.3390/nu12071982. DOI